|By Business Wire||
|February 3, 2014 11:33 AM EST||
Boston Biomedical Associates (BBA) is proud to have supported our client and colleagues at Benvenue Medical, Inc. during The Kiva® System as a Vertebral Augmentation Treatment or KAST trial, and recent 510(k) clearance of the Kiva® VCF Treatment System.
The Kiva System is a novel implant-based solution for vertebral augmentation and a departure from balloon kyphoplasty (BKP), making it the first new approach to the treatment of vertebral compression fractures (VCFs) in over a decade. “We are excited to bring the Kiva System and its clinical benefits to the large and growing population of VCF patients in the US market,” said Robert K. Weigle, CEO of Benvenue Medical, Inc. “The VCF segment has little Level I clinical data, and we are proud to have sponsored one of the largest randomized studies in this space to date,” he added.
BBA partnered with Benvenue Medical Inc. to execute KIVA utilizing a Bayesian Adaptive Design. With this innovative trial design, Benvenue Medical was able to minimize trial sample size needed to demonstrate product safety and effectiveness, thus delivering this new technology to the marketplace sooner. “Benvenue is the kind of client BBA is proud to partner with. They have demonstrated their commitment to strong science, incredible diligence and careful attention to the success of the KIVA program,” said Michelle Michela, Group Leader of Consulting Services at BBA and project lead for the Benvenue Kiva Trial. “We couldn't be prouder of our successful partnership and trial outcome.”
“We are delighted to have worked with a company like BBA that offered us the full spectrum of clinical and data management services, with an integrated approach to study design, data management, statistical analysis and report generation. BBA’s team of industry leading experts was committed to servicing our needs and delivered high-quality results,” said Barbara S. Lindsay, Vice President at Benvenue Medical, Inc.”
Boston Biomedical Associates is a leading Clinical Research Organization known for its comprehensive approach to the clinical trial process. BBA serves as a strategic partner with those involved in the medical device, biotech and pharmaceutical industries, working with them throughout the entire medical product lifecycle to help them bring new technologies to market.
Benvenue Medical, Inc.
Founded in 2004, Benvenue Medical, Inc. develops next-generation, minimally invasive expandable implants for the spine. The company is privately held and funded by Versant Ventures, DeNovo Ventures, Domain Associates and Technology Partners. Its first products are designed for the treatment of vertebral compression fractures and degenerative disc disease, which have combined revenues of $1.6 billion globally. For more information, visit http://www.benvenuemedical.com.
Jul. 6, 2015 11:00 PM EDT Reads: 1,898
Jul. 6, 2015 09:00 PM EDT Reads: 1,151
Jul. 6, 2015 07:45 PM EDT Reads: 1,589
Jul. 6, 2015 07:45 PM EDT Reads: 1,873
Jul. 6, 2015 07:00 PM EDT Reads: 1,084
Jul. 6, 2015 06:15 PM EDT Reads: 1,948
Jul. 6, 2015 05:30 PM EDT Reads: 1,105
Jul. 6, 2015 05:00 PM EDT Reads: 2,154
Jul. 6, 2015 05:00 PM EDT Reads: 1,950
Jul. 6, 2015 04:30 PM EDT Reads: 646
Jul. 6, 2015 04:15 PM EDT Reads: 1,563
Jul. 6, 2015 03:45 PM EDT Reads: 1,759
Jul. 6, 2015 03:00 PM EDT Reads: 1,800
Jul. 6, 2015 03:00 PM EDT Reads: 3,042
"The idea of polyglot persistence is you have to apply the right database for the job - you always have to have many different databases in play. We offer that whole system as a service," explained Raj Singh, Developer Advocate for IBM Cloud Data Services, in this SYS-CON.tv interview at 16th Cloud Expo, held June 9-11, 2015, at the Javits Center in New York City.
Jul. 6, 2015 03:00 PM EDT Reads: 901